secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001193125-25-056122
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine unveils preclinical AATD program with up to 72% gene correction, IND/CTA expected mid-2026
--------------------------------------------------------------------------------

- AATD program targets E342K (Pi*Z) mutation in SERPINA1 gene using LNP-delivered Prime Editors.
- In humanized mice, up to 72% precise correction of SERPINA1 in hepatocytes, restoring >95% serum AAT to corrected isoform.
- Serum M-AAT levels well above 20µM, indicating restoration to normal levels in mouse model.
- Company expects to file IND and/or CTA for AATD program in mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/0001193125-25-056122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312525056122/d908678d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-056122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer